Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Area Qualification In Pharma In 2026: HVAC Qualification, Cleanroom Control, and GMP Compliance Systems

Area qualification helps pharmaceutical manufacturers maintain cleanroom performance, HVAC effectiveness, and environmental control throughout the facility lifecycle. This guide explains qualification requirements, inspection risks, contamination control strategies, and ongoing activities that support GMP compliance and inspection readiness.
  • Blog, Validation and Qualification
GMP facility qualification with cleanroom classification, HVAC validation, environmental monitoring systems, and controlled manufacturing environments.

pharma qualification in 2026: GMP Failures, Validation Gaps, and Inspection Findings

This article explains pharma qualification as a GMP-controlled lifecycle covering equipment, facilities, and utilities. It highlights inspection findings, validation gaps, and regulatory expectations from FDA and EU GMP authorities, focusing on real-world compliance risks and system failures.
  • Blog, Validation and Qualification
Pharma qualification lifecycle and GMP validation concepts including IQ OQ PQ equipment qualification and data integrity requirements in pharmaceutical manufacturing systems

Mayo Clinic Reveals Hidden Limits; AI Can’t Fully Automate Revenue Cycles

Mayo Clinic is applying artificial intelligence across its revenue cycle operations to streamline repetitive administrative workflows, while maintaining human oversight in clinical and billing decisions. Revenue cycle chair Todd Manion shared these insights during an interview at HFMA’s annual conference
  • News
Mayo Clinic Reveals Hidden Limits; AI Can’t Fully Automate Revenue Cycles

FDA Data Sharing Mandate Escalates; CGT Industry Faces System-Wide Transparency Shift

The cell and gene therapy (CGT) industry is facing growing pressure to transform how it develops, manufactures, and commercializes advanced therapies, according to industry experts speaking ahead of BIO 2026. In discussions highlighted by BioSpace on June 22, 2026, leaders
  • News
FDA Data Sharing Mandate Escalates; CGT Industry Faces System-Wide Transparency Shift

pharma regulatory bodies in 2026: FDA, EMA, WHO Roles, and Global GMP Control Systems

This article explores how pharma regulatory bodies such as FDA, EMA, and WHO shape global GMP compliance. It highlights inspection trends, data integrity requirements, and harmonized regulatory frameworks that drive pharmaceutical quality systems and inspection readiness worldwide.
  • Blog, Validation and Qualification
Illustration of FDA, EMA, and WHO regulatory bodies overseeing global GMP inspection readiness, pharmaceutical quality systems, and data integrity requirements in international drug regulatory frameworks.

Pharma Confidence Surges in 2026; While Record M&A and IPO Activity Defy Geopolitical Pressure

Biopharmaceutical industry confidence reached a four-year high in early 2026, according to GlobalData’s State of the Biopharmaceutical Industry 2026 Mid-Year Update, based on a survey of 157 professionals. The report shows 55% of respondents are optimistic about growth despite geopolitical
  • News
Pharma Confidence Surges in 2026; While Record M&A and IPO Activity Defy Geopolitical Pressure

ICH Guidelines in 2026: QMS Integration, GMP Standards, and FDA EMA Harmonization

ICH Guidelines define a global framework for pharmaceutical quality, GMP compliance, and regulatory harmonization. This article explains how ICH Q8, Q9, Q10, and Q12 improve inspection readiness, strengthen quality systems, and align FDA and EMA expectations in practice.
  • Blog, Quality Management System
ICH Q8, Q9, Q10, and Q12 framework supporting Pharmaceutical Quality System, GMP Guidelines compliance, Quality Risk Management, and FDA inspection readiness.

Pharma Deal Slowdown Hits Q1 2026; As AI Partnerships Replace Traditional M&A Logic

Pharma dealmaking slowed in early 2026 as buyers tightened valuation discipline and increased diligence across life sciences transactions. AI partnerships, manufacturing acquisitions, and oncology consolidation are shaping the next phase of pharma deal activity, with recovery expected in late 2026
  • News
Pharma Deal Slowdown Hits Q1 2026; As AI Partnerships Replace Traditional M&A Logic

CNPV Promises Faster Drug Reviews; But Timeline Consistency Breaks

The Food and Drug Administration has introduced its Commissioner’s National Priority Voucher (CNPV) pilot program to accelerate drug and biologic review timelines in the United States. According to industry analysis by Lifescience Dynamics, the program aims to reduce approval timelines
  • News
CNPV Promises Faster Drug Reviews; But Timeline Consistency Breaks

FDA Shock U-Turn on mRNA-1010; From Rejection to Unanimous Vote

Pharmaceutical Executive Daily reports that the FDA Vaccines and Related Biological Products Advisory Committee unanimously voted 9–0 in favor of Moderna’s investigational mRNA-1010 seasonal influenza vaccine for adults aged 50–64 and 65+. The committee confirmed that the benefit-risk profile supports
  • News
FDA Shock U-Turn on mRNA-1010; From Rejection to Unanimous Vote